Skip to content
Clinical Trials – home
Therapeutic area

Musculoskeletal and connective tissue disorders – page 27

  • 872 clinical trials
  • 359 recruiting
  • 331 conditions
  • 28 countries

Conditions in this area

331 conditions with trials, the busiest first

Clinical trials in Musculoskeletal and connective tissue disorders

872 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

872 clinical trials

Study on the Use of Allogenic Adipose-Tissue-Derived Mesenchymal Stem Cells for Healing Chronic Digital Ulcers in Systemic Sclerosis Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Study of Anifrolumab for Children and Teens with Moderate to Severe Lupus

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Tocilizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Osteomyelitis

Recruiting

Study on Early Oral Antibiotic Treatment for Vertebral Osteomyelitis Using Cefuroxime, Dicloxacillin, and Ceftriaxone for Adult Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Rigshospitalet

Study on Reducing Rituximab Dosage for Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:UZ Leuven

Study on Zilucoplan Sodium for Children Aged 2 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Zilucoplan
  • Sponsor:UCB Biopharma

Efficacy and Safety of Givinostat for Non-Ambulant Patients with Duchenne Muscular Dystrophy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Study on the Long-Term Safety of Zilucoplan in Children with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Zilucoplan
  • Sponsor:UCB Biopharma

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Dermatomyositis+2

Recruiting

Study on Filgotinib for Patients with Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Filgotinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.